ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry and rheumatoid arthritis (RA)"

  • Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting

    Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care

    Janet E. Pope1, Emmanouil Rampakakis2 and John S. Sampalis3, 1University of Western Ontario, London, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3Clinical Research, JSS Medical Research, Westmount, QC, Canada

    Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
  • Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting

    The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry

    Ihsan Ertenli1, Omer Karadag1, Yavuz Pehlivan2, Ediz Dalkilic3, Ahmet Mesut Onat4, Bunyamin Kisacik5, Gercek Can6, Servet Akar7, Sedat Capar8, Umut Kalyoncu1, Mustafa Ferhat Oksuz9, Emine Figen Tarhan7 and Nurullah Akkoc6, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 3Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, 4Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 5Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, 6Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, 7Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 8Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, 9Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey

    Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…
  • Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting

    Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients

    Jeffrey R. Curtis1, Jeffrey D. Greenberg2, Leslie Harrold3 and J. Lynn Palmer4, 1University of Alabama at Birmingham, Birmingham, AL, 2Corrona, LLC, Southborough, MA, 3Department of Medicine, UMass Memorial Medical Center, Worcester, MA, 4Corrona Research Foundation, Albany, NY

    Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
  • Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting

    Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry 

    Denis Choquette1, Louis Bessette2, Boulos Haraoui3, Jean-Pierre Raynauld1, Diane Sauvageau1, Angèle Turcotte4, Édith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, 3Université de Montréal, Montreal, QC, Canada, 4Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada

    Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
  • Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting

    Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry

    Seung Min Jung1, Ji Yeon Lee1, Jung Hee Koh1, Seung-Ki Kwok2, Ji Hyeon Ju1, Chong-Hyeon Yoon1 and Sung-Hwan Park1, 1Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…
  • Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting

    An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry

    Jeffrey R. Curtis1, Ying Shan2, Joel M. Kremer3, Katherine Saunders4, Dennis Parenti5 and Shelly Kafka5, 1University of Alabama at Birmingham, Birmingham, AL, 2UMass Memorial Medical Center, Worcester, MA, 3Albany Medical College, Albany, NY, 4Corrona LLC, Atlanta, GA, 5Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
  • Abstract Number: 1437 • 2015 ACR/ARHP Annual Meeting

    Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database

    Bethan Richards1,2, Rachelle Buchbinder3, Marissa N. Lassere4 and Lyn March5, 1Sydney Medical School, University of Sydney, Sydney, Australia, 2Royal Prince Alfred Hospital, Mulgrave, Vic, Australia, 3Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia, 4Dept of Rheumatology, St George Hospital, Kogarah, Australia, 5Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia

    Background/Purpose: Despite advances in the treatments available for rheumatoid arthritis (RA), many patients continue to experience musculoskeletal pain. Untreated and under-treated pain are well known to increase…
  • Abstract Number: 1597 • 2015 ACR/ARHP Annual Meeting

    Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice

    Jacqueline Stewart1, Regan Arendse2, Boulos Haraoui3, Michael Starr4, Denis Choquette5, Michelle Teo6, Dalton Sholter7, Emmanouil Rampakakis8, Eliofotisti Psaradellis9, Brendan Osborne10, Karina Maslova11, Cathy Tkaczyk10, Francois Nantel12 and Allen J Lehman11, 1Penticton Regional Hospital, Penticton, BC, Canada, 2University of Saskatchewan, Saskatoon, SK, Canada, 3Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 4Rheumatology, McGill University, Montreal, QC, Canada, 5Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 6Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, 7Rheumatology Associates, Edmonton, AB, Canada, 8JSS Medical Research, St-Laurent, QC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada, 1219 Green belt Dr, Janssen Inc., Toronto, ON, Canada

    Background/Purpose : Previous studies in rheumatoid arthritis (RA) have shown that patient socioeconomic status (SES) impacts patient prognosis. We hypothesized that public vs. private healthcare…
  • Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting

    Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy

    Vibeke Strand1, Robert J. Holt2, Heather J. Litman3, Jeffrey D. Kent4, Hristina Pashova5, John T. Nguyen3 and Carol J. Etzel6,7, 1Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, 2University of Illinois - Chicago, Chicago, IL, 3Corrona, LLC., Southborough, MA, 4Horizon Pharma USA, Inc., Deerfield, IL, 5Axio Research, LLC., Seattle, WA, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7Corrona, LLC, Southborough, MA

    Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…
  • Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval:  Results from the Corrona US Rheumatoid Arthritis Registry

    Arthur Kavanaugh1, George W. Reed2,3, Katherine C. Saunders2, Andrew S. Koenig4, Jamie Geier5, Joel M. Kremer6, Jeffrey D. Greenberg2,7 and Clifton O. Bingham III8, 1University of California San Diego, La Jolla, CA, 2Corrona, LLC., Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Pfizer, Inc., Collegeville, PA, 5Pfizer, Inc., New York, NY, 6Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 7Rheumatology, New York University School of Medicine, New York, NY, 8Johns Hopkins University, Baltimore, MD

    Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
  • Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting

    Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population

    Boulos Haraoui1, Algis Jovaisas2, William G. Bensen3, Rafat Faraawi4, John Kelsall5, Sanjay Dixit4, Jude Rodrigues6, Maqbool Sheriff7, Emmanouil Rampakakis8, John S. Sampalis8, Allen J Lehman9, Susan Otawa9, Francois Nantel10 and May Shawi10, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 6Clinical Research and Arthritis Centre, Windsor, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
  • Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting

    Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study

    Pratibha Nayak1, Ruili Luo2, Linda Elting2 and Maria E. Suarez-Almazor3, 1General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…
  • Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting

    Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register

    Carl Turesson1, Leszek Stawiarz2, Staffan Lindblad3 and Saedis Saevarsdottir4, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 3Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
  • Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting

    Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register

    Carl Turesson1, Leszek Stawiarz2, Staffan Lindblad3 and Saedis Saevarsdottir4, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 3Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
  • Abstract Number: 418 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients

    Vibeke Strand1, Robert J. Holt2, Katherine C. Saunders3, Jeffery D. Kent4, Ping Xu5, Amy Y. Grahn4, Marc Mason3 and Carol J. Etzel6,7, 1Stanford University, Palo Alto, CA, 2University of Illinois - Chicago, Chicago, IL, 3Corrona, LLC., Southborough, MA, 4Horizon Pharma, Inc., Deerfield, IL, 5Axio Research LLC, Seattle, WA, 6PO Box 786, Corrona, LLC., Southborough, MA, 7Department of Epidemiology, UT MD Anderson, Houston, TX

    Background/Purpose : Morning stiffness is a symptom of rheumatoid arthritis (RA) that is frequently reported and thought to reflect disease activity, but its etiology is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology